top of page
Search
Can machine learning/artificial intelligence improve the clinical success rates of oncology drugs?
Oncology drug development is a multi-billion dollar industry but has a low success rate. How can AI help improve the clinical success rates of oncology drugs?
Dowdy Jackson
May 513 min read
96 views
0 comments
ADC Target Selection Summit Meeting 2024
December 10 – 12, 2024 San Diego, CA Dowdy Jackson, Ph.D. Jackson Consulting Group This year’s ADC Target Selection Summit had...
Dowdy Jackson
Dec 21, 20243 min read
125 views
0 comments
Dowdy Jackson
Sep 30, 20240 min read
233 views
0 comments
The Biosecure Act and its potential impact on the US biotechnology and pharmaceutical industry from a scientist’s perspective
Dowdy Jackson, Ph.D. Jackson Consulting Group The Biosecure Act, H.R.7085 , is a bipartisan legislation that focuses on limiting US...
Dowdy Jackson
Sep 22, 20246 min read
375 views
0 comments
Dowdy Jackson
Jun 30, 20240 min read
172 views
0 comments
Dowdy Jackson
Jun 7, 20240 min read
345 views
1 comment
Bispecific ADCs: A potential game changer for the next generation of ADCs
Dowdy Jackson, Ph.D. Jackson Consulting Group May 10th 2024 Abstract Antibody drug conjugates (ADCs) have become one of the most sought...
Dowdy Jackson
May 11, 20247 min read
1,169 views
0 comments
Antibody Drug Conjugates: Are ADCs a good investment?
Recently, several high-profile ADC deals have been announced. The most prominent deal is Pfizer's acquisition of Seattle Genetics for a...
Dowdy Jackson
Mar 20, 20241 min read
84 views
0 comments
Why The Majority of Oncology Drugs Fail In The Clinic?
Approximately 80-90% of oncology drugs that enter into clinical development (Phase I) never make it to approval (Phase III). Most...
Dowdy Jackson
Sep 13, 20202 min read
88 views
0 comments
bottom of page